Trastuzumab biosimilar (Biocad)

曲妥珠单抗生物类似药 (Biocad)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (Biocad)
Drug Alias NameTrastuzumab (Biocad)曲妥单抗生物仿制药 (Biocad)Trastuzumabum (Biocad)群司珠单抗生物仿制药 (Biocad)trastuzumab biosimilar +[9] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2016/01/01
Country/TerritoryUkraineRussian FederationBelarus +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A